Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

motexafin gadolinium

Known as: Gd (III) Texaphryin, Gadolinium Texaphyrin, Gd(III) texaphyrin 
A synthetic metallotexaphyrin with radiosensitizing and chemosensitizing properties. Motexafin gadolinium accumulates in tumor cells preferentially… Expand
National Institutes of Health

Related topics

Related topics

10 relations

Broader (4)

Antineoplastic AgentsContrast MediaMetalloporphyrinsPhotosensitizing Agents
DNA Breaks, Double-StrandedFree Radical FormationPositive Regulation of Apoptosischemosensitization/potentiation
Expand

Narrower (1)

Xcytrin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Clinical development of photodynamic agents and therapeutic applications
BackgroundPhotodynamic therapy (PDT) is photo-treatment of malignant or benign diseases using photosensitizing agents, light, and… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
Review
2012
Review
2012
Treatment of brain metastases: review of phase III randomized controlled trials.
The optimal management of brain metastases remains controversial. Both whole brain radiotherapy (WBRT) and local treatment… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Review
2010
Review
2010
Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.
Magnetism in medicine has had a long and interesting history. In the 10 th century A.D., Egyptian physician and philosopher… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Review
2006
Review
2006
Motexafin gadolinium: a novel redox active drug for cancer therapy.
Motexafin gadolinium (MGd, Xcytrin) is an aromatic macrocycle that has a strong affinity for electrons, i.e., it is easily… Expand
Highly Cited
2006
Highly Cited
2006
Motexafin Gadolinium, a Tumor-selective Drug Targeting Thioredoxin Reductase and Ribonucleotide Reductase*
Motexafin gadolinium (MGd) is a chemotherapeutic drug that selectively targets tumor cells and mediates redox reactions… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Review
2004
Review
2004
Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.
PURPOSE To report the neurocognitive findings in a phase III randomized trial evaluating survival and neurologic and… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Review
2003
Review
2003
Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.
PURPOSE This phase III randomized trial evaluated survival as well as neurologic and neurocognitive function in patients with… Expand
Highly Cited
1999
Highly Cited
1999
In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.
PURPOSE Gadolinium texaphyrin (Gd-Tex, PCI-0120) is an expanded porphyrin that has demonstrated radiation enhancement. In this… Expand
Highly Cited
1996
Highly Cited
1996
Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI.
Gadolinium(III) texaphyrin (Gd-tex2+) is representative of a new class of radiation sensitizers detectable by magnetic resonance… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Highly Cited
1996
Highly Cited
1996
Lutetium Texaphyrin (PCI‐0123): A Near‐Infrared, Water‐Soluble Photosensitizer
  • S. W. Young, K. Woodburn, +5 authors R. A. Miller
  • Photochemistry and photobiology
  • 1996
    • Corpus ID: 31732810
Lutetium texaphyrin, PCI‐0123, is a pure, water‐soluble photosensitizer with a large broad absorption band centered at 732 nm… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE